Yuflyma
These highlights do not include all the information needed to use YUFLYMA safely and effectively. See full prescribing information for YUFLYMA. YUFLYMA (adalimumab-aaty) injection, for subcutaneous use Initial U.S. Approval: 2023YUFLYMA (adalimumab-aaty) is biosimilar to HUMIRA (adalimumab).
526d626f-8c9f-496c-b838-00a73bb36383
HUMAN PRESCRIPTION DRUG LABEL
Jan 2, 2024
CELLTRION USA, Inc.
DUNS: 116587378
Products 5
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
adalimumab
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (2)
adalimumab
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
adalimumab
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (2)
adalimumab
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
adalimumab
Product Details
FDA regulatory identification and product classification information